欧盟 - 保加利亚文 - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - Средства за дерматит, с изключение на кортикостероиди - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

保加利亚 - 保加利亚文 - Изпълнителна агенция по лекарствата

medochemie ltd. - Амоксицилин и инхибитор на ензима - 875mg/125mg film-coated tablets

保加利亚 - 保加利亚文 - Изпълнителна агенция по лекарствата

Чайкафарма Висококачествените лекарства - Пиперациллин и АСЕ инхибитор - 2 g/0,25 g powder for solution for injection or infusion

保加利亚 - 保加利亚文 - Изпълнителна агенция по лекарствата

actavis group ptc ehf - Имипенем и инхибитор на ензима - 250 mg/250 mg powder for solution for infusion

保加利亚 - 保加利亚文 - Изпълнителна агенция по лекарствата

medochemie ltd., - Амоксицилин и инхибитор на ензима - 1000mg/200mg powder for solution for injection/infusion

保加利亚 - 保加利亚文 - Изпълнителна агенция по лекарствата

krka, d.d. novo mesto - Амоксицилин и инхибитор на ензима - 500 mg/125 mg film - coated tablets 

保加利亚 - 保加利亚文 - Изпълнителна агенция по лекарствата

krka, d.d. novo mesto - Амоксицилин и инхибитор на ензима - 875 mg/125 mg film - coated tablets 

保加利亚 - 保加利亚文 - Изпълнителна агенция по лекарствата

krka, d.d. novo mesto - Амоксицилин и инхибитор на ензима - 400 mg/57 mg/5 ml powder for oral suspension

保加利亚 - 保加利亚文 - Изпълнителна агенция по лекарствата

actavis group ptc ehf. - Пиперациллин и АСЕ инхибитор - 4 g/0,5 g powder for solution for infusion

保加利亚 - 保加利亚文 - Изпълнителна агенция по лекарствата

ГлаксоСмитКлайн ЕООД - Амоксицилин и инхибитор на ензима - 250 mg/62,5 mg/5 ml powder for oral suspension